Samik Pharmaceutical to Be Newly Listed on KOSDAQ on the 27th via SPAC Merger

Samik Pharmaceutical Website

The Korea Exchange announced on October 23 that it has approved the new listing of Samik Pharmaceutical on the KOSDAQ market. The company will be listed through a merger with Hana Financial No. 28 SPAC.

The reference price following the SPAC dissolution merger is 7,480 won, with a par value of 100 won. Trading will begin on October 27. Last year, Samik Pharmaceutical, which is engaged in pharmaceutical manufacturing, recorded sales of 5.45 billion won and an operating profit of 350 million won. The listing advisor is Hana Securities.

This content was produced with the assistance of AI translation services.